| Identification | Back Directory | [Name]
RKI1447 | [CAS]
1342278-01-6 | [Synonyms]
CS-855
RKI1447
RKI-1447
RKI 1447
RKI-1447, >=98%
RKI 1447; RKI1447
RKI1447 USP/EP/BP
7-Pentahydroxyflavone
1-(3-HYDROXYBENZYL)-3-(4-(PYRIDIN-4-YL)THIAZOL-2-YL)UREA
Urea, N-[(3-hydroxyphenyl)methyl]-N'-[4-(4-pyridinyl)-2-thiazolyl]-
RKI-1447, 98%, a potent small molecule inhibitor of ROCK1 and ROCK2
1-[(3-hydroxyphenyl)methyl]-3-(4-pyridin-4-yl-1,3-thiazol-2-yl)urea
1-(3-Hydroxybenzyl)-3-[4-(pyridin-4-yl)thiazol-2-yl]urea RKI 1447
RKI 1447 1-(3-Hydroxybenzyl)-3-[4-(pyridin-4-yl)thiazol-2-yl]urea | [EINECS(EC#)]
200-256-5 | [Molecular Formula]
C16H14N4O2S | [MDL Number]
MFCD26142658 | [MOL File]
1342278-01-6.mol | [Molecular Weight]
326.37 |
| Chemical Properties | Back Directory | [Melting point ]
>205oC (dec.) | [density ]
1.408±0.06 g/cm3(Predicted) | [storage temp. ]
-20°C Freezer | [solubility ]
DMSO (Slightly), Methanol (Slightly, Heated) | [form ]
Solid | [pka]
6.36±0.70(Predicted) | [color ]
Pale Yellow to Pale Beige | [InChI]
InChI=1S/C16H14N4O2S/c21-13-3-1-2-11(8-13)9-18-15(22)20-16-19-14(10-23-16)12-4-6-17-7-5-12/h1-8,10,21H,9H2,(H2,18,19,20,22) | [InChIKey]
GDVRVPIXWXOKQO-UHFFFAOYSA-N | [SMILES]
N(CC1=CC=CC(O)=C1)C(NC1=NC(C2C=CN=CC=2)=CS1)=O |
| Hazard Information | Back Directory | [Description]
RKI-1447 is an inhibitor of the Rho-associated kinases ROCK1 and 2 (IC50s = 14.5 and 6.2 nM, respectively) that functions by binding to the ATP binding site of the kinase. In cancer cells, RKI-1447 at a concentration of 100 nM has been found to suppress the activation of ROCK substrates myosin light chain (MLC)-2 and the MLC phosphatase PP1 regulatory subunit MYPT1 without effect on the phosphorylation of Akt, MEK, or S6 kinase. Furthermore, it can prevent ROCK-mediated migration, invasion, and anchorage-independent growth of MDA-MB-231 breast cancer cells (IC50 = 709 nM). | [Uses]
RKI-1447 is a potent and selective ROCK1 and ROCK2 inhibitor with significant anti-invasive and anti-tumor activies. | [in vivo]
RKI-1447 is highly effective at inhibiting the outgrowth of mammary tumors in a transgenic mouse model. RKI-1447 inhibits mammary tumor growth by 87% and on average the mammary tumors from RKI-1447 treated mice are 7.7 fold smaller compared to those tumors from mice treated with the vehicle control[1]. | [IC 50]
ROCK2: 6.2 nM (IC50); ROCK1: 14.5 nM (IC50) | [References]
[1] patel r a et al. , rki-1447 is a potent inhibitor of the rho-associated rock kinases with anti-invasive and antitumor activities in breast cancer. cancer res, 2012, 72(19): 5025-5034. |
|
| Company Name: |
LETOPHARM LIMITED
|
| Telephone: |
+86-21-5821 5861 |
| Website: |
www.letopharm.com |
|